Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald reaffirmed a buy rating and issued a $24.00 price objective on shares of Corbus Pharmaceuticals in a research report on Wednesday, September 20th. ValuEngine cut Corbus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, September 13th. Finally, BidaskClub raised Corbus Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock has an average rating of Hold and an average price target of $25.00.
Corbus Pharmaceuticals (CRBP) opened at $7.15 on Friday. Corbus Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $10.50.
In related news, Director David P. Hochman bought 5,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average cost of $6.55 per share, for a total transaction of $32,750.00. Following the purchase, the director now owns 459,500 shares in the company, valued at $3,009,725. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director David P. Hochman bought 10,000 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were bought at an average price of $7.08 per share, with a total value of $70,800.00. Following the completion of the purchase, the director now owns 459,500 shares in the company, valued at approximately $3,253,260. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 25,336 shares of company stock valued at $175,632. Company insiders own 11.90% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System purchased a new stake in Corbus Pharmaceuticals during the 3rd quarter valued at $108,000. Yellowstone Partners LLC purchased a new stake in Corbus Pharmaceuticals during the 3rd quarter valued at $110,000. Voya Investment Management LLC purchased a new stake in Corbus Pharmaceuticals during the 2nd quarter valued at $125,000. Capital Fund Management S.A. purchased a new stake in Corbus Pharmaceuticals during the 2nd quarter valued at $130,000. Finally, Credit Suisse AG purchased a new stake in Corbus Pharmaceuticals during the 1st quarter valued at $157,000. Institutional investors and hedge funds own 27.84% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Corbus Pharmaceuticals (CRBP) Earns Buy Rating from Noble Financial” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/18/corbus-pharmaceuticals-crbp-earns-buy-rating-from-noble-financial.html.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
What are top analysts saying about Corbus Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corbus Pharmaceuticals and related companies.